Modified vitamin K-dependent polypeptides
AssigneeRegents of the University of Minnesota
InventorGary L. Nelsestuen
Life of this patent
Estimating the term…
Abstract
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
Claims31
A vitamin K-dependent polypeptide comprising a modified GLA domain that enhances membrane binding affinity and activity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising a glutamic acid residue at the position corresponding to position 34 of SEQ ID NO:5.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a vitamin K-dependent polypeptide, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain that enhances membrane binding affinity and activity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising a glutamic acid residue at the position corresponding to position 34 of SEQ ID NO:5.
A method of increasing clot formation in a mammal comprising administering an amount of a vitamin K-dependent polypeptide effective to increase clot formation in said mammal, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain that enhances membrane binding affinity and activity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising a glutamic acid residue at the position corresponding to position 34 of SEQ ID NO:5.
Dependencies are inferred from the claim text.